- Home
- ZNTL vs VATE Comparison
ZNTL vs VATE Comparison
Compare ZNTL & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- VATE
- Stock Information
- Founded
- ZNTL 2014
- VATE 1994
- Country
- ZNTL United States
- VATE United States
- Employees
- ZNTL N/A
- VATE N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- VATE Metal Fabrications
- Sector
- ZNTL Health Care
- VATE Industrials
- Exchange
- ZNTL Nasdaq
- VATE Nasdaq
- Market Cap
- ZNTL 102.2M
- VATE 98.2M
- IPO Year
- ZNTL 2020
- VATE 1996
- Fundamental
- Price
- ZNTL $1.28
- VATE $5.42
- Analyst Decision
- ZNTL Buy
- VATE
- Analyst Count
- ZNTL 9
- VATE 0
- Target Price
- ZNTL $8.69
- VATE N/A
- AVG Volume (30 Days)
- ZNTL 689.9K
- VATE 45.1K
- Earning Date
- ZNTL 05-14-2025
- VATE 05-06-2025
- Dividend Yield
- ZNTL N/A
- VATE N/A
- EPS Growth
- ZNTL N/A
- VATE N/A
- EPS
- ZNTL N/A
- VATE N/A
- Revenue
- ZNTL $26,865,000.00
- VATE $1,066,100,000.00
- Revenue This Year
- ZNTL N/A
- VATE N/A
- Revenue Next Year
- ZNTL N/A
- VATE N/A
- P/E Ratio
- ZNTL N/A
- VATE N/A
- Revenue Growth
- ZNTL N/A
- VATE N/A
- 52 Week Low
- ZNTL $1.01
- VATE $3.25
- 52 Week High
- ZNTL $13.00
- VATE $13.79
- Technical
- Relative Strength Index (RSI)
- ZNTL 41.45
- VATE 40.07
- Support Level
- ZNTL $1.18
- VATE $5.63
- Resistance Level
- ZNTL $1.27
- VATE $8.28
- Average True Range (ATR)
- ZNTL 0.07
- VATE 0.69
- MACD
- ZNTL 0.01
- VATE -0.05
- Stochastic Oscillator
- ZNTL 26.67
- VATE 0.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.